Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug
Capricor Therapeutics shares plunged after FDA staff flagged data and efficacy concerns regarding its Duchenne heart disease therapy.
Evidence dossier
Intelligence passport
Measured timeline
-
Detected
-
Evidence threshold reached
-
Latest coverage observed
-
Peak measured velocity
-
Outcome review added
The reporting (15)
-
-
-
FDA staff report throws cold water on Capricor's DMD cell therapy bidFirstWord Pharma · 113d ago
-
-
Adcom ‘cage match’ in store for Capricor?BioWorld News · 114d ago
-
Capricor Provides Update on Deramiocel for DMD Ahead of FDA MeetingIntellectia AI · 114d ago
-
FDA scientists question Capricor data; Legend CEO steps downBioPharma Dive · 114d ago
-
-
-
Capricor Therapeutics (CAPR) Secures New Headquarters Tied To FDA Decision On Deramiocelsimplywall.st · 114d ago
-
-
-
FDA staff flags data concerns about Capricor's therapy; shares plungeReuters · 114d ago
-
Is Capricor Therapeutics (CAPR) Trading At A Discount After Its Lease Deal And FDA Wait?Yahoo Finance · 114d ago
-
What happened
- Velocity & Diffusion: Coverage exploded across 13 distinct news outlets with 15 published articles, achieving a live velocity of 14.
- Primary Driver: Capricor Therapeutics shares plunged after FDA staff flagged data and efficacy concerns regarding its Duchenne heart disease therapy.
- Predictive Outlook: Archynetys algorithmic models forecast this story will fade from trending status over the next 24 hours.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
The FDA has raised questions about the efficacy and data of Capricor Therapeutics' drug intended to treat Duchenne heart disease. These concerns were raised ahead of a scheduled hearing.
Coverage from Reuters, STAT, and WTVB emphasizes the FDA staff's flags regarding the therapy, while Reuters notes a subsequent plunge in company shares. Yahoo Finance and MarketBeat report on the stock's current trading status, including a lease deal and a high volume of call options purchased by traders.
Attention now turns to the upcoming hearing to address the FDA's concerns. Coverage does not yet specify the date of the hearing or the exact nature of the data discrepancies.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. Updated 113d ago.
Questions people are asking
What did the FDA flag regarding Capricor's therapy?
FDA staff flagged concerns regarding the efficacy and data of the Duchenne heart disease therapy.
How did the market react to the FDA news?
According to Reuters, shares of Capricor Therapeutics plunged following the reports.
What other market activity is noted for CAPR?
MarketBeat reports that stock traders have purchased a large volume of call options on the company.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.
Topics
Related trends
The GLP-1 boom has a dark side
The FDA has ordered new eye-risk warnings on a dozen GLP-1 drugs including Ozempic and Zepbound, escalating safety scrutiny of the blockbuster weight-loss class.
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
FDA rejects Summit's ivonescimab, halting the first PD-1xVEGF bispecific antibody from reaching the US market.
FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness
The FDA has ordered new warning labels on blockbuster GLP-1 drugs Ozempic and Zepbound over a rare eye condition linked to sudden blindness, shaking confidence in the red-hot weight-loss market.
‘I’m destroyed.’ Owner speaks on E. coli outbreak that shut down SLO County farm
Brookshire Farms faces shutdown after an E. coli outbreak sickens fifteen, including three children with kidney failure, and co‑owner declares 'I'm destroyed'.
DEA And Marijuana Rescheduling Opponents File Final Briefs In Hearing Ahead Of Judge's Decision
Judge's decision looms on marijuana rescheduling as opponents file final briefs.
Breakthrough: FDA Approves First Drug Offering a 'Functional Cure' For Chronic Hepatitis B
The FDA approved Hibsago, the first drug offering a functional cure for chronic hepatitis B, after clinical trials showed 19% of patients achieved undetectable virus levels that persisted after treatment ended.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.